Jaguar Health, Inc. JAGX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Jaguar Health, Inc. reported revenue across 3 products and services; the largest, Mytesi, was $11M, 98.4% of the filed sum (-2.7% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Mytesi$11M98.4%-2.7% yoy
- Canalevia$148K1.3%-7.5% yoy
- Neonorm$35K0.3%+25.0% yoy
Members sum to $11.2M against $11.5M consolidated (residual $328K) - eliminations or corporate lines the filer did not tag on this axis.
- License$19M93.9%+44186.0% yoy
- Product$1.2M5.9%-44.5% yoy
- Grant$25K0.1%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.